uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Camzyos
Authorised
Human
Details
EMA number
EMEA/H/C/005457
ATC code
C01EB
Authorisation
26 June 2023
Revision
6
EMA page
Therapeutic indication
Treatment of symptomatic obstructive hypertrophic cardiomyopathy.
MeSH:
Cardiomyopathy, Hypertrophic
Group:
Other cardiac preparations
Special characteristics
Additional monitoring
Active substances
Mavacamten
Marketing Authorisation Holder
Bristol-Myers Squibb Pharma EEIG
MAH
Timeline
Filter by authority:
EMA
Camzyos authorised
26 Jun 2023
authorised
regulatory
Camzyos | uMedical